Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

First OTC Birth Control Pill Approved In US Will Launch With Three-Year Market Exclusivity

Jul 13 2023

• By Malcolm Spicer

• Source: Shutterstock/HBW Insight

Related Content

Perrigo’s First National Brand, Nasonex OTC Switch, Will Have Familiar Buzz In Advertising

Mar 21 2022

Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC

Jun 24 2022

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Jul 12 2022

Opill AdCom Delay Not Unusual – Will Evaluation Of US OTC Switch Proposal Continue In The Norm?

Nov 03 2022

OTC Oral Contraceptive Interest Could Be Price Sensitive, Study Suggests

Feb 19 2018

Perrigo Prioritizes Innovating First After Following OTC Brands To Market

Sep 10 2019

HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives

Jul 09 2021

Biden Calls For Expanding Access To Reproductive Health Care, Including OTC Oral Contraceptives

Jun 23 2023

First OTC Oral Contraceptive Has Advisory Panel’s Unanimous Support Despite FDA’s Data Concerns

May 11 2023

Perrigo’s Pivot To Building Brand Market Share Boosted With Opill OTC Oral Contraceptive Approval

Jul 13 2023

Related Companies

Perrigo Company PLC

Merck & Co., Inc.

GSK plc

Additional Topics

International United States US States Prescription To OTC Switch Women's Health Approvals Business Strategies Commercial Companies Compliance Consumer Drug Approval Standards Drug Review FDA Ingredients Manufacturing OTC Drugs Policy Politics Regulation Retail Safety

More from Rx-to-OTC Switch

More from Health

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window